ArticleFrontiers in public health2026
ESG performance, financing constraints, and workplace health investment: evidence from Chinese biopharmaceutical enterprises.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Workplace health promotion (WHP) is critical for occupational health management, yet empirical evidence on determinants of corporate health investment remains limited. This study examines whether ESG performance promotes workplace health investment in Chinese biopharmaceutical enterprises and investigates the mediating role of financing constraints. Methods: Using panel data from 55 A-share listed biopharmaceutical companies (2015-2023, 495 firm-year observations), we employed fixed effects models with manually collected health expenditure data. The three-step method tested financing constraints as a mediator. Heterogeneity analyses and multiple endogeneity treatments were conducted. Results: ESG performance significantly promotes workplace health investment ( Conclusion: ESG performance effectively promotes workplace health investment by alleviating financing constraints, providing empirical support for integrating occupational health promotion into corporate sustainability strategies. Theoretically, this study bridges corporate finance and occupational health research by revealing the transmission mechanism of "ESG → financing constraint alleviation → workplace health expenditure." Practically, the findings suggest that ESG improvement can serve as a market-based lever for promoting organizational investment in employee health programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.